Efficacy and Safety of Lactobacillus acidophilus LA-5 and Bifidobacterium lactis BB-12 Combination in Gastroenterology, Pediatrics and Allergology

Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(2):113-124

​ Andreeva I.V., Stetsiouk O.U.
probiotic Lactobacillus Bifidobacterium
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(2):113-124

Abstract

Bifidobacterium lactis BB-12 and Lactobacillus acidophilus LA-5 are the well-known probiotic strains. This review presents data on efficacy of the administration of BB-12 and LA-5 strains in several GI tract disorders: treatment of diarrhea, prevention of antibiotic-associated diarrhea, adjuvant therapy of Helicobacter pylori-associated diseases, treatment of functional constipation, and normalization of bowel function. The data on multiple effects of BB-12 and LA-5 strains on immune system function (decrease in rate of respiratory tract infections in children, prevention and treatment of atopic diseases) are also described. A focus on safety of probiotic administration, including the use in vulnerable patient populations, is made.

Irina V. Andreeva

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Olga U. Stetsiouk

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Jungersen M., Wind A., Johansen E., et al. The science behind the probiotic strain Bifidobacterium animalis subsp. lactis BB-12®. Microorganisms 2014; 2:92-110.
  • 2. Reid G. Regulatory and clinical aspects of dairy probiotics. FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina. 2001:1-34.
  • 3. Saavedra J.M. Clinical applications of probiotic agents. Am J Clin Nutr 200; 73:1147S-51S.
  • 4. Reid G., Jass J., Sebulsky M.T., et al. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16:658-72.
  • 5. D’Souza A.L., Rajkumar C., Cooke J., et al. Probiotics in prevention of antibiotic associated diarrhoea: metaanalysis. BMJ 2002; 324:1361.
  • 6. Holzapfel W.H., Haberer P., Geisen R., et al. Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr 2001; 73:365-73.
  • 7. Marcos A., Warnberg J., Nova E., et al. The effect of milk fermented by yogurt cultures plus Lactobacillus casei DN-114001 on the immune response of subjects under academic examination stress. Eur J Nutr 2004; 43:381-9.
  • 8. Monachese M., Burton J.P., Reid G. Bioremediation and tolerance of humans to heavy metals through microbial processes: a potential role for probiotics? Appl Environ Microbiol 2012; 78:6397-404.
  • 9. Андреева И.В., Стецюк О.У. О штаммоспецифичности пробиотиков. Клин микробиол антимикроб химиотер 2010; 12:253-4.
  • 10. van der Waaij D. Colonization resistance of the digestive tract — mechanism and clinical consequences. Nahrung 1987; 31:507-17.
  • 11. Vernazza C.L., Gibson G.R., Rastall R.A. Carbohydrate preference, acid tolerance and bile tolerance in five strains of Bifidobacterium. J Appl Microbiol 2006; 100:846-53.
  • 12. Martins F.S., Silva A.A., Vieira A.T., et al. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol 2009; 191:623-30.
  • 13. Collado M.C., Meriluoto J., Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol 2007; 45:454-60.
  • 14. Gorbach S.L. Lactic acid bacteria and human health. Ann Med 1990; 22:37-41.
  • 15. Plockova M., Tomanova J., Chumchalova J. Inhibition of mould growth and spore production by Lactobacillus acidophilus CH5 metabolites. Bull Food Res 1997; 36:237-47.
  • 16. Tejada-Simon M.V., Lee J.H., Ustunol Z., et al. Ingestion of yogurt containing Lactobacillus acidophilus and Bifidobacterium to potentiate immunoglobulin A responses to cholera toxin in mice. J Dairy Sci 1999; 82:649-60.
  • 17. Ouwehand A.C., Salminen S., Tölkkö S., et al. Resected human colonic tissue: new model for characterizing adhesion of lactic acid bacteria. Clin Diagn Lab Immunol. 2002; 9:184-6.
  • 18. Juntunen M., Kirjavainen P.V., Ouwehand A.C., et al. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol 2001; 8(2):293-6.
  • 19. Collado M.C., Jalonen L., Meriluoto J., et al. Protection mechanism of probiotic combination against human pathogens: in vitro adhesion to human intestinal mucus. Asia Pac J Clin Nutr 2006; 15(4):570-5.
  • 20. Kekkonen R. Immunomodulatory Effects of Probiotic Bacteria In Healthy Adults. Academic Dissertation. Helsinki. 2008. 122 p.
  • 21. Pitkala K.H., Strandberg T.E., Finne Soveri U.H., et al. Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial. J Nutr Health Aging 2007; 11:305-11.
  • 22. Uchida K., Akashi K., Kusunoki I., et al. Effect of fermented milk containing Bifidobacterium lactis BB-12® on stool frequency, defecation, fecal microbiota and safety of excessive ingestion in healthy female students. J Nutr Food 2005; 8:39-51.
  • 23. Nishida, S., Gotou, M., Akutsu, S., et al. Effect of yogurt containing Bifidobacterium lactis BB-12 on improvement of defecation and fecal microflora of healthy female adults. Milk Sci 2004; 53:71-80.
  • 24. Eskesen D., Jespersen L., Michelsen B., et al. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12(R), on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallelgroup trial. Br J Nutr 2015; 114:1638-46.
  • 25. Kainifar H., Ahanchian H., Grover Z., et al. Synbiotic in the management of infantile colic: a randomised controlled trial. J Paediatr Child Health 2014; 50:801-5.
  • 26. Saavedra J.M., Abi-Hanna A., Moore N., et al. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr 2004; 79:261-7.
  • 27. Chouraqui J.P., Van Egroo L.D., Fichot M.C. Acidified milk formula supplemented with Bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr 2004; 38:288-92.
  • 28. Saavedra J.M., Bauman N.A., Oung I., et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344:1046-9.
  • 29. Chatterjee S., Kar P., Das T., Ray et al. Randomised placebocontrolled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India 2013; 61:708-12.
  • 30. Fox M.J., Ahuja K.D., Robertson I.K., et al. Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study. BMJ Open 2015; 5: e006474.
  • 31. Wenus C., Goll R., Loken E.B., et al. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr 2008; 62:299-301.
  • 32. de Vrese M., Kristen H., Rautenberg P., et al. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. J Dairy Res 2011; 78:396-403.
  • 33. Sheu B.S., Wu J.J., Lo C.Y., et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16:1669-75.
  • 34. Smith T.J., Rigassio-Radler D., Denmark R., et al. Effect of Lactobacillus rhamnosus LGG(R) and Bifidobacterium animalis ssp. lactis BB-12(R) on health-related quality of life in college students affected by upper respiratory infections. Br J Nutr 2013; 109:1999-2007.
  • 35. Taipale T., Pienihakkinen K., Isolauri E., et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr 2011; 105:409-16.
  • 36. Rautava S., Salminen S., Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy — a randomised, double-blind, placebo-controlled study. Br J Nutr 2009; 101:1722-6.
  • 37. Isolauri E. Dietary modification of atopic disease: use of probiotics in the prevention of atopic dermatitis. Curr Allergy Asthma Rep 2004; 4:270-5.
  • 38. Kalliomaki M., Isolauri E. Role of intestinal flora in the development of allergy. Curr Opin Allergy Clin Immunol 2003; 3:15-20.
  • 39. Rautava S., Kalliomaki M., Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002; 109:119-21.
  • 40. Isolauri E., Arvola T., Sutas Y., et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30:1604-10.
  • 41. Hanifin J.M., Cooper K.D., Ho V.C., et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/ American Academy of Dermatology Association «Administrative Regulations for Evidence-Based Clinical Practice Guidelines». J Am Acad Dermatol 2004; 50:391-404.
  • 42. Прошутинская Д.В., Чикин В.В., Знаменская Л.Ф. и соавт. Федеральные клинические рекомендации по ведению больных атопическим дерматитом. Российское общество дерматовенерологов и косметологов. Москва,2015-35с.
  • 43. Lee Y.K., Salminen S. Handbook of Probiotics and Prebiotics. 2nd ed: Wiley-Interscience; 2009.
  • 44. Manson J.E., Tosteson H., Ridker P.M., et al. The primary prevention of myocardial infarction. N Engl J Med 1992; 326:1406-16.
  • 45. Klaver F.A., van der Meer R. The assumed assimilation of cholesterol by Lactobacilli and Bifidobacterium bifidum is due to their bile salt-deconjugating activity. Appl Environ Microbiol 1993; 59:1120-4.
  • 46. Pereira D.I., Gibson G.R. Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. Crit Rev Biochem Mol Biol 2002; 37:259-81.
  • 47. Tonucci L.B., Olbrich Dos Santos K.M., Licursi de Oliveira L., et al. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin Nutr 2015.
  • 48. Mohamadshahi M., Veissi M., Haidari F., et al. Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: A randomized controlled clinical trial. J Res Med Sci 2014; 19:531-6.
  • 49. Ejtahed H.S., Mohtadi-Nia J., Homayouni-Rad A., et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci 2011; 94:3288-94.
  • 50. Guidelines for the Evaluation of Probiotics in Food. Joint FAO/WHO (Food and Agriculture Organization/World Health Organisation) Working Group. London, Ontario, Canada: 2002.
  • 51. Marteau P. Safety aspects of probiotic products. Scand J Nutr 2001; 45:22-4.
  • 52. Mackay A.D., Taylor M.B., Kibbler C.C., et al. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999; 5:290-2.
  • 53. Rautio M., Jousimies-Somer H., Kauma H., et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999; 28:1159-60.
  • 54. Salminen M.K., Rautelin H., Tynkkynen S., et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38:62-9.
  • 55. Land M.H., Rouster-Stevens K., Woods C.R., et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115:178-81.
  • 56. Hempel S., Newberry S., Ruelaz A., et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) 2011; 200:1-645.
  • 57. van den Nieuwboer M., Claassen E., Morelli L., et al. Probiotic and synbiotic safety in infants under two years of age. Benef Microbes 2014; 5:45-60.
  • 58. van den Nieuwboer M., Brummer R.J., Guarner F., et al. Safety of probiotics and synbiotics in children under 18 years of age. Benef Microbes 2015; 6:615-30.
  • 59. Van den Nieuwboer M., Brummer R.J., Guarner F., et al. The administration of probiotics and synbiotics in immune compromised adults: is it safe? Benef Microbes 2015; 6:3-17.
  • 60. Dugoua J.J., Machado M., Zhu X., et al. Probiotic safety in pregnancy: a systematic review and metaanalysis of randomized controlled trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp. J Obstet Gynaecol Can 2009; 31:542-52.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared